Clinical Trials Browser

OTHER × pembrolizumab × CNS × Clear all

NCT02287428 2026-04-17

Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM

Phase 1 Active not recruiting

Glioblastoma

NCT05064280 2026-04-16

Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases

Phase 2 Recruiting

Brain Neoplasms, Neoplasms

NCT04659811 2026-04-15

Stereotactic Radiosurgery and Immunotherapy (Pembrolizumab) for the Treatment of Recurrent Meningioma

Phase 2 Active not recruiting

Meningioma

NCT03277638 2026-04-09

Laser Interstitial Thermotherapy (LITT) Combined With Checkpoint Inhibitor for Recurrent GBM (RGBM)

Phase 1/2 Active not recruiting

Brain Neoplasms, Glioblastoma

NCT07301268 2026-04-08

GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma

Phase 2 Recruiting

Astrocytoma, Glioblastoma, Gliosarcoma

NCT01822652 2026-04-06

GRAIN

Phase 1 Active not recruiting

Neuroblastoma, Recurrence

NCT06514898 2026-04-03

MATCHPOINT

Phase 1 Active not recruiting

Medulloblastoma

NCT03449238 2026-03-30

Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients

Phase 1/2 Recruiting

Brain Neoplasms, Breast Neoplasms

NCT03197506 2026-03-25

Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma

Phase 2 Active not recruiting

52 enrolled 19 charts

Glioblastoma, Gliosarcoma

NCT04074096 2026-03-25

BEPCOME-MB

Phase 2 Active not recruiting

CNSDermatologic

Brain Neoplasms, Melanoma

NCT02852655 2026-03-20

A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive Glioblastoma

Phase 1 Active not recruiting

60 enrolled 19 charts

Brain Neoplasms

NCT02896335 2026-03-12

Palbociclib and Pembrolizumab In Central Nervous System Metastases

Phase 2 Recruiting

Brain Neoplasms

NCT02858869 2026-03-09

Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases

Phase 1 Completed

25 enrolled 14 charts

CNSDermatologicThoracic

Uveal Melanoma, Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma

NCT05188508 2026-03-06

Pembrolizumab, Olaparib, and Temozolomide for People With Glioma

Phase 2 Recruiting

Glioma

NCT05463848 2026-03-04

Surgical Pembro +/- Olaparib w TMZ for rGBM

Phase 2 Recruiting

Glioblastoma

NCT02658279 2026-03-03

Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype

Phase NA Active not recruiting

Glioma

NCT07410676 2026-02-18

EBNK-ST-001

Phase 1/2 Recruiting

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicOther hematologic neoplasmSarcomaThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Bronchogenic, Disease, Esophageal Neoplasms, Glioblastoma, Kidney Neoplasms, Leukemia, Liver Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms

NCT04348747 2026-02-12

Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer

Phase 2 Recruiting

Brain Neoplasms, Triple Negative Breast Neoplasms

NCT03405792 2026-02-06

2-THE-TOP

Phase 2 Active not recruiting

40 enrolled 11 charts

Glioblastoma

NCT07385846 2026-02-04

Pilot Study of Navigated Focused Ultrasound and Pembrolizumab in the Treatment of Recurrent WHO Grade 4 IDH-Wildtype Glioblastoma With Mismatch Repair Deficiency

Phase 1 Not yet recruiting

Turcot syndrome, Glioblastoma

NCT02721732 2026-01-29

Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic

Phase 2 Active not recruiting

157 enrolled 26 charts

CNSEndocrineGenitourinary

Adrenal Cortex Neoplasms, Carcinoma, Renal Cell, Neoplasm Metastasis, Neoplasms, Unknown Primary, Paraganglioma, Penile Neoplasms, Pheochromocytoma, Carcinoma, Small Cell, Vascular Neoplasms

NCT03279692 2026-01-29

Phase II Trial of Pembrolizumab in Recurrent or Residual High Grade Meningioma

Phase 2 Active not recruiting

26 enrolled 14 charts

Meningioma

NCT05084430 2026-01-22

Study of Pembrolizumab and M032 (NSC 733972)

Phase 1/2 Recruiting

Astrocytoma, Glioblastoma, Recurrence, Gliosarcoma

NCT07347210 2026-01-16

MATVAC-1

Phase 2 Not yet recruiting

Primary Glioblastoma

NCT05465954 2026-01-12

Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma

Phase 2 Recruiting

Glioblastoma, Gliosarcoma

NCT03873818 2026-01-09

Low Dose Ipilimumab With Pembrolizumab in Treating Patients With Melanoma That Has Spread to the Brain

Phase 2 Completed

24 enrolled 13 charts

CNSDermatologic

Brain Neoplasms, Melanoma

NCT06558214 2026-01-07

OPTIMUS PRIME

Phase 2 Recruiting

Glioblastoma

NCT04955743 2025-11-24

Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma

Phase 2 Terminated

CNSDermatologicGenitourinary

Brain Neoplasms, Carcinoma, Renal Cell, Melanoma

NCT04483778 2025-11-20

B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults

Phase 1 Active not recruiting

CNSDermatologicGastrointestinalGenitourinaryOther solid neoplasmSarcoma

Carcinoma, Melanoma, Neoplasms, Germ Cell and Embryonal, Wilms Tumor, Neuroblastoma, Retinoblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Sarcoma, Synovial, Hepatoblastoma, Sarcoma, Clear Cell, Neurofibrosarcoma, Rhabdoid Tumor, Desmoplastic Small Round Cell Tumor

NCT04964960 2025-10-31

Pembro+Chemo in Brain Mets

Phase 2 Terminated

3 enrolled 7 charts

Brain Neoplasms, Lung Neoplasms, Neoplasms

NCT03426891 2025-10-06

Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma

Phase 1 Completed

21 enrolled 12 charts

Brain Neoplasms, Glioblastoma

NCT07199413 2025-09-30

Allogeneic, Antigen-Presenting, GM-CSF-secreting, SV-BR-1-GM Whole Cell-Therapeutic Vaccine and Immunotherapy: A Phase I Pilot Safety and Feasibility Study for Solid Tumor Patients With CNS Metastases

Phase 1 Not yet recruiting

Brain Neoplasms, Meningeal Carcinomatosis

NCT06822543 2025-09-29

TROPICAL-1

Phase 2 Recruiting

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03347617 2025-09-09

Ferumoxytol MRI in Assessing Response to Pembrolizumab in Patients With Glioblastoma

Phase 2 Terminated

52 enrolled 15 charts

Glioblastoma

NCT04977375 2025-09-03

Trial of Anti-PD-1 Immunotherapy and Stereotactic Radiation in Patients With Recurrent Glioblastoma

Phase 1/2 Recruiting

Brain Neoplasms, Glioblastoma, Glioma, Spinal Cord Neoplasms, Central Nervous System Neoplasms

NCT04201873 2025-08-22

Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma

Phase 1 Active not recruiting

Glioblastoma

NCT02337686 2025-08-15

Pembrolizumab in Treating Patients With Recurrent Glioblastoma

Phase 2 Active not recruiting

18 enrolled 12 charts

NCT07011849 2025-08-13

Study of Lenvatinib Plus Pembrolizumab in IO Refractory mRCC Patients With Brain Metastases

Phase 2 Withdrawn

CNSGenitourinary

Brain Neoplasms, Carcinoma, Renal Cell

NCT04118036 2025-08-11

Abemaciclib + Pembrolizumab In Glioblastoma

Phase 2 Withdrawn

Glioblastoma

NCT02681549 2025-08-07

Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer (NSCLC)

Phase 2 Completed

41 enrolled 20 charts

CNSDermatologicThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma

NCT05341349 2025-07-30

Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain Metastases

Phase 1 Active not recruiting

CNSDermatologic

Uveal Melanoma, Brain Neoplasms, Melanoma

NCT04729348 2025-07-25

Pembrolizumab And Lenvatinib In Leptomeningeal Metastases

Phase 2 Terminated

Meningeal Carcinomatosis

NCT02311582 2025-05-29

MK-3475 in Combination With MRI-guided Laser Ablation in Recurrent Malignant Gliomas

Phase 1/2 Completed

55 enrolled 14 charts

Glioma

NCT03665545 2025-05-13

IMA950-106

Phase 1/2 Completed

Glioblastoma

NCT05669352 2025-04-04

A Study of Oral IRAK-4 Inhibitor CA-4948 in Combination With Pembrolizumab and Stereotactic Radiosurgery in Patients With Melanoma Brain Metastases

Phase 1/2 Suspended

CNSDermatologic

Brain Neoplasms, Melanoma

NCT06749925 2025-04-01

Clinical Trial Assessing the Efficacy and Safety of Dendritic Cell-Based Immunotherapy for Glioblastoma

Phase 3 Not yet recruiting

Glioblastoma

NCT03016091 2025-02-18

A Trial of Pembrolizumab for Refractory Atypical and Anaplastic Meningioma

Phase 2 Terminated

18 enrolled 9 charts

Hemangiopericytoma, Meningioma

NCT02960230 2025-01-22

H3.3K27M Peptide Vaccine With Nivolumab for Children With Newly Diagnosed DIPG and Other Gliomas

Phase 1/2 Completed

50 enrolled 12 charts

Diffuse Intrinsic Pontine Glioma, Glioma

NCT05879120 2024-11-20

Randomized Study of Neo-adjuvant and Adjuvant Pembrolizumab With and Without Targeted Blood Brain Barrier Opening Using Exablate MRI-guided Focused Ultrasound (Exablate MRgFUS) for Recurrent Glioblastoma

Phase 2 Withdrawn

Glioblastoma

NCT06640582 2024-11-05

BAH2472

Phase 1/2 Recruiting

Brain Neoplasms, Glioblastoma, Glioma, Meningioma